SCHEMBL25387804

SCHEMBL25387804

CC(C)(C)c1ccc(-c2cc(O)cc(Cl)c2)c(C(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.46
CNR2 P34972 4/20 0.46
AKR1C2 P52895 3/20 0.40
AKR1C3 P42330 2/20 0.40
ACLY P53396 1/20 0.39
ALDH1A1 P00352 4/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 3/20 0.37
TYR P14679 2/20 0.37
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
GAA P10253 2/20 0.36
AKR1C1 Q04828 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25387140 0.89 ALDH1A1 (0.44) CNR1CNR2ALDH1A1ALOX15HSD17B10
SCHEMBL27193588 0.89 CNR1 (0.47) CNR1CNR2AKR1C2AKR1C3ACLY
SCHEMBL28147029 0.78 LMNA (0.54) AKR1C2AKR1C3ALDH1A1ALOX15HSD17B10
SCHEMBL8708320 0.78 HSD17B1 (0.42) CNR1CNR2ALDH1A1ALOX15HSD17B10
SCHEMBL30496503 0.78 PGR (0.42) CNR1CNR2ALDH1A1LMNAKMT2A
SCHEMBL30496142 0.74 KIF11 (0.43) AKR1C2AKR1C3ALDH1A1ALOX15HSD17B10
SCHEMBL2357462 0.73 ALDH1A1 (0.48) ALDH1A1ALOX15HSD17B10HPGDTDP1
SCHEMBL29763177 0.73 ALDH1A1 (0.48) ALDH1A1ALOX15HSD17B10HPGDTDP1
SCHEMBL3262676 0.71 LMNA (0.44) ACLYALDH1A1ALOX15HSD17B10HPGD
SCHEMBL4856979 0.70 HDAC4 (0.49) CNR1CNR2ALDH1A1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12598915-B2 Condensed cyclic compound, light-emitting device including the condensed cyclic compound, and electronic apparatus including the light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2026-04-07 US disclosed
CN-116574116-A Condensed cyclic compound, light-emitting device including the same, and electronic device 三星显示有限公司 2023-08-11 CN disclosed
US-20230255100-A1 CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-10 US disclosed
US-20230255100-A1 CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-10 US disclosed
US-20230255100-A1 CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12598915-B2 Condensed cyclic compound, light-emitting device including the condensed cyclic compound, and electronic apparatus including the light-emitting device RFC1, CRY1, SCO2 CNR1 191/4885CNR2 649/4885AKR1C2 1803/4885
US-20230255100-A1 CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE CRY1, CCNE2, NCAPH CNR1 2177/4885CNR2 2610/4885AKR1C2 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.